Table of Contents
Type 1 diabetes affects roughly 9-10 million people worldwide - and for most, treatment still means lifelong insulin and constant monitoring.
Phaim is taking an antigen-specific approach, aiming to switch off the immune attack at the root of disease - starting in T1DM, with follow-ons in psoriasis, RA, and MS.
Preclinical animal data in DMX4001 showed improved and normalized blood glucose levels and promising T-cell function.
At JPM 2026, Onyx spoke with co-founders Nara Daubeney PhD and Professor Piers Daubeney to find out more.
A special thanks to our Onyx Live sponsors:
HUMPHREYS LAW - a focused, full-service law firm advising clients in the technology and media sectors. https://humphreys.law/
Panacea - AI-powered FDA consultants. File your IND in half the time. https://withpanacea.com/
I hope you enjoy watching!
Yours sincerely,
Dr. Adil Ali
Comments